Scarica l'app Stockscreener
37.72
2.78%
1.02
Pre-mercato:
37.72
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock - Investing.com
TradingKey - TradingKey
Stifel reiterates Buy on Rapport Therapeutics stock, $56 target By Investing.com - Investing.com Canada
Rapport Therapeutics(RAPP.US) 10% Shareholder Sells US$11.09 Million in Common Stock - Moomoo
Third Rock funds trim Rapport Therapeutics (RAPP) stake under Rule 10b5-1 plan - Stock Titan
Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144 - Stock Titan
Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock sells 697,500 RAPP shares (RAPP) in April–May 2026 - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A 34% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rapport Therapeutics (NASDAQ:RAPP) Posts Earnings Results, Beats Estimates By $0.25 EPS - MarketBeat
Third Rock Ventures sells 426,005 RAPP shares (NASDAQ: RAPP) - Stock Titan
Rapport Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market - TipRanks
(RAPP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines - ChartMill
Earnings Flash (RAPP) Rapport Therapeutics, Inc. Reports Q1 Revenue $20.0M, vs. FactSet Est of $7.5M - marketscreener.com
Rapport Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.42) — 10-Q Summary - TradingView
Collaboration deal lifts Rapport Therapeutics (NASDAQ: RAPP) revenue and cash - Stock Titan
Cash runway to 2H 2029 as Rapport (NASDAQ: RAPP) advances RAP-219 - Stock Titan
Seizure drug posted 90% cut as Rapport says cash lasts to 2029 - Stock Titan
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update - GlobeNewswire
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Rapport Therapeutics advances RAP-219 after strong Phase 2a data - The Globe and Mail
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $46 - Moomoo
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):